



Supplementary Figures**Supplemental Figure 1**

Supplemental Figure 1. **Short-term treatment with P2RX7 agonist induces FosB induction in MC3T3 osteoblastic cells.** MC3T3-E1 cells were treated with vehicle (V), 250 μ M BzATP (B) or 1 μ g/mL PMA (P) for 5 min. The wells were subsequently washed twice with HBSS and incubated at 37 $^{\circ}$ C with fresh complete MEM- α media for the indicated times and immunoblotted for FosB expression. A representative immunoblot displaying FosB/ Δ FosB protein expression in each cell line is shown (n = 3). The results of three independent experiments were combined and represent relative FosB from short-term treatment (mean \pm SEM).

Supplemental Figure 2



Supplemental Figure 2. **ERK1/2 kinase inhibitor attenuates P2RX7-induced AP-1 protein expression in primary human monocytes.** Purified peripheral blood monocytes from five separate patients were pre-treated for 15 min with either vehicle (DMSO) or the MEK-1/2 inhibitor UO126 at the indicated concentrations. The cells were subsequently treated with either vehicle (2.5 mM HEPES) or 250 μ M BzATP for 2 h. A representative immunoblot displaying FosB protein expression is shown. Densitometry results were combined and are represented as a percent of BzATP-induced AP-1 protein expression (mean \pm SEM). * $p < 0.05$ compared to vehicle pre-treated BzATP-induced FosB/JunB expression.